Zhongsheng Pharmaceutical Co., Ltd.: three major class 1 new drug researches are included in the "national major project"

Recently, Zhongsheng pharmaceutical announced that the special subjects of "phase I / II clinical research on the treatment of non-alcoholic steatohepatitis with zsp1601, a class I new chemical drug", "phase I / II clinical research on the treatment of idiopathic pulmonary fibrosis with zsp1603, a class I new chemical drug" and "phase I / II clinical research on the treatment of late stage malignant tumor with zsp1602, a class I chemical new drug" applied by the company have been listed in the national "major new drug creation" department As the second batch of projects for the implementation plan of new drugs in 2018, the major technology projects Phase I / II clinical study on the treatment of nonalcoholic steatohepatitis with zsp1601, a new chemical drug of class 1, No.: 2018zx09201002-002-001 unit of responsibility: Guangdong Zhongsheng Pharmaceutical Co., Ltd Zsp1601 is the first in class innovative drug developed by the company for the treatment of nonalcoholic steatohepatitis, which has a new chemical structure and a new target of action It is the first innovative drug to enter the clinical trials for the treatment of NASH in China Zsp1601 is currently in phase I clinical trial, and the project is progressing smoothly Phase I / II clinical study no of zsp1603, a new chemical class 1 drug, in the treatment of idiopathic pulmonary fibrosis: 2018zx09201002-002-002 responsible unit: Guangdong Zhongsheng Pharmaceutical Co., Ltd Zsp1603 is an innovative drug developed by the company with clear mechanism and independent intellectual property rights for the treatment of idiopathic pulmonary fibrosis (IPF) and malignant tumors It is the first small molecule innovative drug approved for clinical treatment of IPF at the same target in China Zsp1603 is currently in phase I clinical trial, and the project is progressing smoothly Zsp1602, a new chemical class 1 new drug, is an innovative drug developed by Guangdong Zhongsheng Pharmaceutical Co., Ltd with clear mechanism of action and independent intellectual property rights for the treatment of malignant tumors Zsp1602 is currently in phase I clinical trial, and the project is progressing smoothly According to the notice on the second batch of projects for the implementation plan of major science and technology projects of "major new drug creation" in 2018 (wksh [2018] No 676) and the task contract for major national science and technology projects (minkou) signed by the company, the above three projects of the company have obtained the central financial appropriation2, 2.0367 million yuan, the financial funds will be paid in installments from 2018 to 2020 Recently, the company has received a total of 11.1368 million yuan of the above-mentioned financial funds, and the time for the remaining financial funds to arrive at the account depends on the allocation progress of the national financial department Zhongsheng pharmaceutical said that in recent years, the company has continued to increase investment in research and development, carried out research and development of several innovative drugs, promoted strategic transformation and upgrading of the company, and actively participated in major national science and technology projects The above special subject has been successfully listed in the national "major new drug creation" science and technology major special project, which is highly recognized for zsp1601, zsp1602 and zsp1603 innovative R & D projects, which is helpful to accelerate the development of innovative drug R & D projects and the process of drug listing The full text of the announcement is as follows: